What is a "mini-tender" offer and why is Boston Scientific advising shareholders to reject it?

A mini-tender offer is an offer to purchase a small percentage of a company's outstanding shares, often at a price below the current market value. Companies like Boston Scientific advise rejection because these offers can be confusing, may involve fees that reduce the net proceeds, and shareholders might receive less than they could by selling on the open market through a broker. The offer from TRC Capital Corporation is unsolicited and potentially not in the best interest of BSX shareholders.

How many shares are involved in TRC Capital Corporation's offer, and what percentage of Boston Scientific's total shares does this represent?

TRC Capital Corporation's offer is to purchase up to three million shares of Boston Scientific's common stock. This amount represents a very small fraction of the company's total outstanding shares, specifically up to 0.217%.

What are the risks for shareholders if they accept the mini-tender offer?

Shareholders who accept a mini-tender offer risk selling their shares at a price lower than the current market value. Additionally, they may incur fees or charges associated with the offer, further reducing their net proceeds. There's also the risk of not having their shares accepted if more than the target number of shares are tendered. Boston Scientific's recommendation suggests these risks outweigh any perceived benefit of the offer.

What should a shareholder do if they are considering selling their Boston Scientific shares?

Boston Scientific recommends rejecting the unsolicited mini-tender offer. Instead, shareholders who wish to sell their shares are advised to consider selling them through a broker on the open market. This typically provides a better price and more transparency compared to unsolicited mini-tender offers.

BSX 8-K: Regulation FD — Jul 24, 2018

Summary

Boston Scientific Corporation (BSX) has filed an 8-K report on July 24, 2018, primarily to disclose a press release regarding an unsolicited "mini-tender" offer from TRC Capital Corporation. The company is formally recommending that its stockholders reject this offer. TRC Capital Corporation's offer seeks to purchase up to three million shares of BSX common stock, which represents a very small fraction (up to 0.217%) of the total outstanding shares. This action by BSX is a proactive measure to protect its shareholders from potentially disadvantageous terms often associated with such unsolicited offers. The company's communication emphasizes that the mini-tender offer is unsolicited and urges shareholders to exercise caution. While the offer may appear attractive on the surface, mini-tender offers typically involve purchasing shares at a price below the current market value, and shareholders may incur fees or charges. Boston Scientific's recommendation to reject the offer is intended to ensure shareholders are aware of the potential risks and to encourage them to consider alternative strategies for selling their shares, such as through a broker on the open market.

Key Highlights

1Boston Scientific (BSX) issued a press release on July 24, 2018, advising shareholders to reject a mini-tender offer.
2The unsolicited offer is from TRC Capital Corporation, seeking to purchase up to 3 million shares of BSX common stock.
3The tendered shares represent a minimal percentage (up to 0.217%) of BSX's total outstanding shares.
4The company is advising caution to its shareholders regarding the unsolicited offer.
5BSX's recommendation is that shareholders reject the mini-tender offer, implying it may not be in their best interest.
6This 8-K filing is primarily for Regulation FD disclosure purposes, including the press release as an exhibit.

BOSTON SCIENTIFIC CORP 8-K Report, Regulation FD Disclosure (Jul 24, 2018)

Summary

Key Highlights

Frequently Asked Questions